(Q67665191)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1695690%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

title

Nuclear deoxyribonucleic acid ploidy and serum prostate specific antigen in operable prostatic adenocarcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1695690%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

Nuclear Deoxyribonucleic Acid Ploidy and Serum Prostate Specific Antigen in Operable Prostatic Adenocarcinoma (English)

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

1 November 2022

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

1 November 2022

author name string

O. Nativ

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1695690

1 November 2022

R. P. Myers

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1695690

1 November 2022

G. M. Farrow

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1695690

1 November 2022

T. M. Therneau

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1695690

1 November 2022

H. Zincke

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1695690

1 November 2022

M. M. Lieber

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1695690

1 November 2022

language of work or name

English

0 references

publication date

1 August 1990

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1695690%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

16 September 2019

https://api.elsevier.com/content/article/PII:S0022534717394375?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

https://api.elsevier.com/content/article/PII:S0022534717394375?httpAccept=text/plain

1 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

http://www.jurology.com/doi/pdf/10.1016/S0022-5347%2817%2939437-5

1 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

1 November 2022

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1695690%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

volume

144

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1695690%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

page(s)

303-306

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1695690%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

issue

2 Pt 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1695690%20AND%20SRC:MED&resulttype=core&format=json

Proceedings: The natural history of prostatic cancer

16 September 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

The clinical spectrum of prostate cancer

1 November 2022

2

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

The natural history of prostate cancer

1 November 2022

5

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging

1 November 2022

7

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

Nuclear roundness factor: a quantitative approach to grading in prostatic carcinoma, reliability of needle biopsy tissue, and the effect of tumor stage on usefulness

1 November 2022

8

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

Nucleolar grading of prostatic adenocarcinoma: Light microscopic correlation with disease progression

1 November 2022

9

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer

1 November 2022

10

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

Stage D1 prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometry

1 November 2022

12

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

1 November 2022

13

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

An evaluation of prostate specific antigen in prostatic cancer

1 November 2022

14

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

Hormone therapy in prostatic cancer

1 November 2022

15

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

The present status of radical prostatectomy for stages A and B prostatic cancer

1 November 2022

16

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

T.N.M. classification for urological tumours (U.I.C.C.) - 1974

1 November 2022

17

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

Radical retropubic prostatectomy and pelvic lymphadenectomy for high-stage cancer of the prostate

1 November 2022

18

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

Pathologic Differentiation and Prognosis of Prostatic Carcinoma

1 November 2022

19

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry

1 November 2022

21

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

A Detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis

1 November 2022

22

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

Mathematical analysis of DNA distributions derived from flow microfluorometry

1 November 2022

24

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

The prognostic value of DNA ploidy combined with histologic substaging for incidental carcinoma of the prostate gland

1 November 2022

25

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

Relationship between DNA ploidy, glandular differentiation, and tumor spread in human prostate cancer

1 November 2022

26

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

Prostatic carcinoma cell DNA content measured by flow cytometry and its relation to clinical outcome

1 November 2022

27

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy

1 November 2022

28

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

Stage C prostatic adenocarcinoma: flow cytometric nuclear DNA ploidy analysis

1 November 2022

29

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis

1 November 2022

31

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

Serum Prostatic Antigen Measurement in Localized Prostatic Cancer: Correlation with Clinical Course

1 November 2022

33

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer

1 November 2022

34

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers

1 November 2022

35

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease

1 November 2022

36

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer.

1 November 2022

37

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

This month in Investigative Urology: prostate-specific antigen

1 November 2022

38

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients

1 November 2022

39

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)39437-5

1 November 2022

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1695690%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

1 reference